All News
German Society of Rheumatology COVID Pandemic Recommendations
The Annals of Rheumatic Disease has published the preliminary recommendations of the German Society of Rheumatology for the management of Inflammatory rheumatic diseases patients during the SARS-CoV-2/Covid-19 pandemic.
These preliminary recommendations are based on an expert consensus from 17 experienced German rheumatologists.
Links:
Dr. John Cush RheumNow ( View Tweet)
IL-6 Inhibitors May Benefit COVID-19 Infection
In the last few days there have been encouraging "preliminary" reports that IL-6 inhibition by either tocilizumab or sarilumab may be efficacious in patients with severe coronavirus infections.
TNF Inhibitors Reduce and Stabilize Coronary Plaque
Arthritis & Rheumatology reports that biologic (bDMARD) use in rheumatoid arthritis may decrease cardiovascular disease risk by retarding coronary plaque formation and progression (especially non‐calcified and low‐attenuation plaque).
Read ArticleHigh Dose Chloroquine Harmful in Severe COVID-19
JAMA Open Network reports an interim analysis of the Brazilian CloroCovid-19 trial showing thta higher doses of chloroquine (CQ) in the treatment of severe COVID-19 was associated with QTc interval prolongation and increased mortality.
Read ArticleDr. John Cush RheumNow ( View Tweet)
RheumNow Podcast – In Times of Trouble (4.24.20)
Dr Jack Cush reviews the news, journal reports, twitter feed and COVID developments from the past week on RheumNow.com
Read ArticlePotential Role of B Cells in COVID
A pre-proof letter to the editor in the Journal of Allergy and Clinical Immunology presents a series of patients with immunoglobulin deficiency disorders and how they differentially responded when infected with the coronavirus.
They identified seven Primary Antibody Deficiencies patients with COVID-19 infection; five affected with Common Variable Immune Deficiencies and two affected with Agammaglobulinemia, one with X-linked Agammaglobulinemia and one with Autosomal Recessive Agammaglobulinemia.
FDA Consumer Warnings on Cannabis and CBD
The FDA issued a new consumer update on what you need to know about Cannabis or Cannabis-derived Compounds, Including CBD. This is part of the FDA effort to answer questions about the science, safety, and quality of products containing cannabis and cannabis-derived compounds, particularly CBD.
Read ArticleNIH Consensus Guidelines for the Treatment of COVID-19
A National Institutes of Health (NIH) expert panel has developed consensus treatment guidelines for the management of coronavirus (COVID-19). To date no drug has been proven to be safe and effective for treating COVID-19. Moreover, they found no evidence to recommended the use of hydroxychloroquine for prophylaxis or treatment of COVID-19 outside of a current clinical trial.
Read ArticleCOVID-19 and the Slippery Road of Cytokine Storms
Early reports on the COVID-19 pandemic allude to a cytokine storm or hyper-inflammation, especially in patients who succumbed to the illness.
Read ArticleLower Risk of Diabetes with Abatacept
Patients with rheumatoid arthritis (RA) treated with abatacept (Orencia) had a lower risk of developing diabetes mellitus compared with those receiving certain tumor necrosis factor (TNF) inhibitors, a large cohort study suggested.
Read ArticleTuesday Nite Rheumatology Grand Rounds - Febrile Disorders
Dr. Jack Cush reviews the appproach to evaluating fever in adults suspected of having a rheumatic disease, Stills disease or autoinflammatory conditions.
Read ArticleRheumNow Podcast – Drive Them Crazy (4.17.20)
Dr. Jack Cush reviews the news, journal articles and new ACR COVID-19 guidelines from the past week on RheumNow.com.
Physical Therapy Superior to Steroid Injection for Knee OA
Treatment options for painful knee osteoarthritis (OA) are numerous, but comparative outcomes are seldom available. A NEJM report shows that physical therapy is superior to intraarticular glucocorticoids injections assessing the outcomes 12 months after the intervention.
Read ArticleCOVID-19 Systemic Involvement
The presentations of the COVID-19 infection have been clearly chronicled with the worrisome onset of sore throat, dry cough, loss of smell and taste with fevers, myalgias, fatigue and the worrisome progression of pulmonary involvement in a minority. Lab findings may include a leukocytosis,
Read ArticleRituximab in Rheumatoid Vasculitis
The Journal of Rheumatology reports a retrospective, single center, analysis of 17 rheumatoid vasculitis patients who responded well to intravenous rituximab (RTX) therapy.
Read ArticlePost 9/11 Autoimmune Disease Risk
The 9/11/01 terrorist attach on the World Trade Center (WTC) resulted in at least 2,977 fatalities, over 25,000 injuries, and caused at least $10 billion in infrastructure and property damage. Arthritis & Rheumatology reports that dust cloud exposure among responders and
Read ArticleGuselkumab a Hit in Phase III for PsA
The monoclonal antibody guselkumab (Tremfya), which binds the interleukin (IL)-23 p19 subunit, was effective for psoriatic arthritis in two large clinical trials, providing comprehensive benefits for this heterogeneous disorder, investigators reported in The Lancet.
Read Article